GENEVA / Dec 31, 2024 / Business Wire / Alcon (SIX/NYSE: ALC) CEO David Endicott will present at the 2025 J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 4:30 p.m. PST.
A live webcast of the conference will be available at investor.alcon.com/news-and-events/events-and-presentations.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.
Connect with us on
| Last Trade: | US$72.60 |
| Daily Change: | 0.55 0.76 |
| Daily Volume: | 2,446,803 |
| Market Cap: | US$35.890B |
September 16, 2025 September 08, 2025 August 26, 2025 August 19, 2025 August 05, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
